苯达莫司汀治疗经泊马度胺治疗难治的多次预处理的多发性骨髓瘤的疗效病例
A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide.
作者信息
Cerchione Claudio, Nappi Davide, Di Perna Maria, Zacheo Irene, Migliaccio Ilaria, Salvatore Dalila, Picardi Marco, Pane Fabrizio, Catalano Lucio
机构信息
Hematology Azienda Ospedaliera Universitaria Federico II Via Pansini 5 Naples 80131 Italy.
出版信息
Clin Case Rep. 2017 Mar 8;5(4):505-507. doi: 10.1002/ccr3.773. eCollection 2017 Apr.
Abstract
In this report, we would like to highlight the efficacy of bendamustine in a heavily pretreated patient, also refractory to pomalidomide. It is conceivable that different therapy combinations in heavily treated Multiple myeloma (MM) have to be explored, without "a priori" exclusion of ancient drugs, even after failure of the ultimate pharmacological options.
摘要
在本报告中，我们想强调苯达莫司汀在一名经过大量预处理、对泊马度胺也耐药的患者中的疗效。可以想象，对于经过大量治疗的多发性骨髓瘤（MM）患者，即使在最终的药物治疗方案失败后，也必须探索不同的治疗组合，而不能“先验地”排除使用古老的药物。
相似文献
1
A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide.
Clin Case Rep. 2017 Mar 8;5(4):505-507. doi: 10.1002/ccr3.773. eCollection 2017 Apr.
2
Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.
Turk J Haematol. 2017 Aug 2;34(3):233-238. doi: 10.4274/tjh.2016.0397. Epub 2017 Mar 8.
3
Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Future Oncol. 2017 Feb;13(5s):7-9. doi: 10.2217/fon-2016-0460.
4
Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party.
Blood Res. 2016 Sep;51(3):193-199. doi: 10.5045/br.2016.51.3.193. Epub 2016 Sep 23.
5
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
6
Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
Future Oncol. 2017 Feb;13(5s):3-6. doi: 10.2217/fon-2016-0368.
7
Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.
Hematol Oncol. 2016 Dec;34(4):200-207. doi: 10.1002/hon.2199. Epub 2015 Mar 18.
8
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Chemotherapy. 2019;64(2):110-114. doi: 10.1159/000502473. Epub 2019 Sep 18.
9
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
10
Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma.
Case Rep Hematol. 2016;2016:6745286. doi: 10.1155/2016/6745286. Epub 2016 Oct 27.
引用本文的文献
1
Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report.
Medicine (Baltimore). 2020 Aug 14;99(33):e21440. doi: 10.1097/MD.0000000000021440.
2
Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support.
Support Care Cancer. 2019 May;27(5):1587-1588. doi: 10.1007/s00520-019-4651-5. Epub 2019 Jan 23.
本文引用的文献
1
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone.
Support Care Cancer. 2016 Dec;24(12):4835-4837. doi: 10.1007/s00520-016-3430-9. Epub 2016 Oct 10.
2
Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.
Eur J Haematol. 2016 May;96(5):544. doi: 10.1111/ejh.12705. Epub 2015 Dec 28.
3
How I treat relapsed myeloma.
Blood. 2015 Mar 5;125(10):1532-40. doi: 10.1182/blood-2014-10-551531. Epub 2015 Jan 13.
4
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Blood. 2014 Mar 20;123(12):1826-32. doi: 10.1182/blood-2013-11-538835. Epub 2014 Jan 13.
5
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Blood. 2014 Feb 13;123(7):985-91. doi: 10.1182/blood-2013-08-521468. Epub 2013 Nov 13.
6
Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.
J Clin Oncol. 2011 Oct 1;29(28):3805-12. doi: 10.1200/JCO.2011.34.9290. Epub 2011 Sep 6.
Zotero 插件